Work

Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States.

Year: 2025

Type: conference-abstract

Source: JCO Oncology Practice

DOI: 10.1200/op.2025.21.10_suppl.17

Authors: Feng Qian, Arielle G. Bensimon, Anjela Tzontcheva, Kimberly Thomas Benjamin, Ravindra Uppaluri, Douglas Adkins, Geoffrey Johnson, Catherine Fernan, Dandan Zheng, Yuexin Tang, Dominic Muston

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Analysis Group (United States), Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Washington University in St. Louis

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4414893323

Cites:

Cited by:

Related to: